Summary
• BioRestorative Therapies, Inc. (BRTX) shares fell 6.99% in after-hours trading to $1.33, retracing from recent highs.
• The company has a scheduled Type B meeting with the FDA for its BRTX-100 treatment, aimed at chronic lumbar disc disease.
• Despite challenges and a 95.9% stock decline over three years, analysts rate BRTX as a “Buy.”
BioRestorative Therapies, Inc. (BRTX) is experiencing a decline of 6.99% in after-hours trading, with shares priced at $1.33, down from the last close of $1.43. This movement comes without a fresh catalyst as the stock retraces from recent highs.
Aiming for FDA Approval
On November 17, 2025, BioRestorative announced that it was granted a Type B meeting with the FDA to discuss an accelerated Biologics License Application (BLA) pathway for its BRTX-100 treatment, targeting chronic lumbar disc disease. This has positioned the company favorably within the regenerative medicine landscape. The previous earnings report on November 12 indicated an earnings surprise of zero, with the actual loss per share aligned with estimates at $0.38.
Financial Metrics and Performance Snapshot
BRTX’s performance metrics reveal ongoing challenges. The stock is currently $1.11, showing significant negative deviations from key moving averages: -23.3% on the 20-day SMA, -28.4% on the 50-day SMA, and -35.9% on the 200-day SMA. The stock has suffered a 95.9% drop over the past three years and a 24.7% decline in the past six months, further emphasizing the volatility with a monthly performance at -18.0%.
Volatility and Trading Volume
The average volume over the past ten days stood at 173,088 shares, while the three-month average is slightly lower at 159,246. During today’s session, BRTX saw a trading volume of 35,030 shares, highlighting lower-than-average activity and contributing to the stock’s declining price action.
Analyst Sentiment
Despite the downward trend, the analyst rating for BRTX remains a “Buy.” This rating reflects an incomplete reassessment of the company amid the backdrop of its recent activities and FDA interactions. Investors appear to remain hopeful about the potential of BRTX-100 and its implications for BioRestorative’s market position.
With the latest update now reflected in trading, investors will be monitoring how the stock’s volume and momentum develop in the next session.